Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trialDavid Marín, Katayoun Rezvani, May Daher et al.|Nature Medicine|2024Cited by 452
Substance P inhibits natural killer cell cytotoxicity through the neurokinin-1 receptorLinda Monaco-Shawver, Jordan S. Orange, Lynnae Schwartz et al.|Journal of Leukocyte Biology|2010Cited by 37